At 51.5%, Donor IVF at Ages 38–40 Outperforms Fresh IVF Under 35 — What the CDC Data Actually Shows

The Number That Inverts the Conventional Wisdom

The standard fertility narrative runs like this: the younger you start IVF, the better your odds. Clinics publish age-stratified success rates. Reproductive endocrinologists counsel patients to begin sooner rather than later. The implication is that time is the primary variable.

The CDC's own data complicates that story considerably.

In 2022, women aged 38 to 40 undergoing IVF with donor eggs achieved a live birth rate of 51.5%. Women under 35 undergoing IVF with their own fresh eggs — the population assumed to have the best odds — achieved 48.0%. The older cohort, by three and a half percentage points, outperformed the younger one.

That is not a rounding error. That is a structural finding about what actually drives IVF success, and it has direct implications for how patients should evaluate their treatment options.

What the Data Covers and Why the Source Matters

These figures come from the CDC's Assisted Reproductive Technology (ART) national surveillance program, which collects cycle-level data from every fertility clinic in the United States. Unlike clinic-reported marketing statistics, the CDC data is standardized, audited, and disaggregated by age group, egg type (own versus donor), and transfer method (fresh versus frozen).

The 2022 dataset captures transfers that reflect the current standard of care: widespread use of preimplantation genetic testing (PGT), improved vitrification protocols, and freeze-all strategies that have largely replaced fresh transfers at many clinics. The 2019 dataset offers a useful prior baseline.

Comparing the two years reveals something additional worth noting. The under-35 fresh non-donor live birth rate moved from 46.6% in 2019 to 48.0% in 2022 — a 1.4 percentage point gain over three years. That is incremental progress. The technology is improving, but not dramatically. What shifted the curve more dramatically is the increasing adoption of donor egg protocols, particularly among women in their late 30s and early 40s who previously might have continued attempting cycles with their own eggs past the point of diminishing returns.

Age Is Not the Variable. Egg Quality Is.

Here is the inference the data supports: when clinics and researchers say "age reduces IVF success," they are using age as a proxy for egg quality. Oocyte quality declines with age. Chromosomal abnormalities in embryos become more frequent. Implantation fails more often because the genetic material is compromised, not because the uterus itself has aged meaningfully.

This distinction matters enormously in practice.

When you replace the age-compromised variable — the patient's own eggs — with donor oocytes from a younger woman, the age of the recipient becomes largely irrelevant to the embryo's genetic competence. The uterine environment of a 40-year-old, properly prepared with hormone support, can sustain a healthy pregnancy at rates comparable to or exceeding those of a younger woman using her own eggs.

The 51.5% live birth rate for the 38–40 donor cohort is evidence of exactly this mechanism. These women did not have better outcomes than their younger counterparts because of some anomalous clinic effect or patient selection bias. They had better outcomes because the donor egg protocol removed the primary failure mode — egg quality — from the equation.

The data for women aged 43–44 using frozen donor eggs reinforces this. Their live birth rate in 2022 was 46.5%. Compare that to the 46.6% live birth rate for women under 35 using their own fresh eggs in 2019. A woman a decade older, using frozen donor eggs, matched the success rate of the benchmark young-patient cohort with fresh non-donor embryos. Not approximately matched. Matched within a tenth of a percentage point.

What Clinics Typically Present Versus What the Data Shows

This is where the gap between how fertility care is marketed and how it actually works becomes consequential for patients.

Most clinic success rate presentations lead with age-stratified fresh non-donor cycles. That is the number on the billboard, the number in the consultation handout, and often the number that drives a patient's initial assessment of whether IVF is "worth trying" at her age. If a 39-year-old sees that fresh non-donor success rates in her age group run 20–25% per transfer, she may conclude that IVF is a low-probability proposition for her.

That conclusion is not wrong for fresh non-donor cycles. But it is incomplete if she has not been clearly presented with the donor egg alternative and its actual performance data.

The 51.5% figure for women in her age bracket using donor eggs is not a fine-print footnote. It is the most clinically relevant number for a significant fraction of patients in their late 30s and early 40s — specifically, those whose diminished ovarian reserve or prior poor-response cycles suggest that their eggs, not their uterus, are the limiting factor.

The question every patient in this demographic should be asking is not "what is the IVF success rate for my age?" It is "what is the IVF success rate for my egg quality profile?" Those are different questions, and the answer to the second one often leads to a different treatment path.

The Frozen Versus Fresh Protocol Shift

There is a secondary pattern in the data that deserves attention: the shift from fresh to frozen transfers and its effect on outcomes.

Fresh transfers were the standard for decades. An egg retrieval would be followed, in the same cycle, by fertilization, embryo culture, and uterine transfer. The problem is that the stimulation medications required for egg retrieval alter the hormonal environment of the uterus in that same cycle — sometimes meaningfully enough to reduce receptivity.

The widespread adoption of freeze-all protocols — where embryos are biopsied for PGT, frozen, and transferred in a subsequent cycle with a hormonally primed uterus — has changed the calculus. The 2019 data for women aged 35–37 using frozen non-donor embryos showed a 40.7% live birth rate. That number, taken in isolation, looks modest. But in context, it represents a frozen cohort that is older than the under-35 fresh group — and closes much of the gap.

What the 2022 data confirms is that frozen transfer outcomes have continued to improve, particularly in donor egg cycles, where the combination of high-quality donated oocytes and optimized frozen embryo transfer protocols produces consistently strong results. The 46.5% frozen donor rate for women 43–44 is a product of both improvements: better donor selection and better transfer timing.

Patients evaluating IVF should understand that "fresh" is not automatically superior to "frozen." For many patient profiles, particularly those undergoing PGT or using donor eggs, a frozen transfer in a subsequent cycle may produce better outcomes than a fresh transfer would in the same retrieval cycle.

How to Interpret These Numbers for Your Own Situation

Aggregate success rates are starting points, not predictions. A 51.5% national average for the 38–40 donor cohort tells you what the population experienced. Your individual outcome depends on variables that aggregate data cannot capture: donor egg quality, clinic-specific laboratory conditions, protocol design, and your own endometrial receptivity history.

That said, there are three questions this data should prompt any patient in her late 30s or early 40s to ask her reproductive endocrinologist directly.

First: what does my ovarian reserve testing suggest about the likely quality of my eggs relative to a donor? Anti-Müllerian hormone (AMH) levels and antral follicle count give a rough proxy for reserve; PGT results from prior cycles, if available, give a more direct read on egg quality.

Second: if my clinic's donor egg success rates are materially below the CDC national average of 51.5% for the 38–40 cohort, what accounts for that gap? This is not a hostile question. It is the same due diligence any patient would apply to any high-cost medical procedure. Clinics that cannot explain a gap relative to national benchmarks deserve scrutiny.

Third: at what point in my own-egg cycle history does the data suggest I should reassess? Three failed transfers with chromosomally normal embryos is a different situation than three failed transfers with untested embryos — and each points to different clinical interventions.

If you want to benchmark your clinic's reported outcomes against what the CDC data shows for comparable protocols and age groups, the Feralyx dataset lets you explore the full IVF outcome breakdown by age cohort, transfer type, and egg source — pulling from the same federal surveillance data but organized for decision-making rather than regulatory reporting.

The Framing Problem That Costs Patients Time and Money

There is a broader issue here that extends beyond any individual treatment decision.

Patients who delay considering donor egg protocols — either because they were not presented with the option clearly or because the framing around donor eggs carries cultural weight that makes it feel like an admission of failure — often spend years and significant money on own-egg cycles past the point where the data would have suggested reconsidering.

The average IVF cycle using a patient's own eggs costs between $12,000 and $15,000 before medications. A fresh donor egg cycle typically runs $25,000 to $35,000, depending on donor compensation, agency fees, and whether the clinic uses a fresh versus frozen donor bank. That price differential is real and meaningful.

But the comparison is not one own-egg cycle versus one donor cycle. For patients with poor prognosis who cycle multiple times with their own eggs — which is common — the cumulative cost of persistence can exceed the cost of transitioning to donor eggs earlier. More importantly, multiple failed cycles carry emotional and physical costs that do not appear in the financial comparison.

The data does not tell any individual patient what to do. What it does is provide a clearer view of the probability landscape than most patients receive in a standard consultation. A 51.5% success rate for a cohort that is older than the national "benchmark" age group is a signal worth taking seriously — not as a mandate, but as a data point that should be on the table from the first conversation, not the fifth.

The aggregate CDC numbers are national. Your clinic's numbers may diverge significantly. Running your clinic's reported rates against the Feralyx database puts both figures in context, so the comparison you're making is informed rather than anecdotal.

What the Three-Year Trend Suggests

The improvement in IVF outcomes from 2019 to 2022 is modest at the aggregate level — roughly 1–2 percentage points across most cohorts. But the consistency of the improvement across age groups and protocol types suggests it is real, not noise.

The drivers are well-documented: better embryo culture media, more precise endometrial receptivity testing, genetic screening of embryos before transfer, and improved cryopreservation techniques. None of these are revolutionary breakthroughs in the 2019–2022 window. They are incremental refinements accumulating into a slightly better baseline.

The more meaningful structural change is the shift in clinical thinking about who is a donor egg candidate and when that conversation should happen. The 38–40 cohort achieving 51.5% is, in part, a product of better patient selection — more precise identification of which patients are likely to benefit from donor protocols, earlier in their treatment history.

As that clinical judgment improves further, the aggregate outcomes for older cohorts should continue to improve, even before any underlying technology advances. Better matching of patient profiles to protocols is itself a form of progress.

The takeaway is not that IVF success is guaranteed for any patient at any age with the right protocol. It is that the relationship between age and outcome is far less deterministic than the conventional framing suggests — and that for a substantial fraction of patients over 38, the highest-probability path may look different from the default first recommendation.

Related Analysis

Other Smart Technology Investments tools that bear on this decision:

• Toravine: medicare, plan, advantage
• DriveDecision: vehicle, car, tco
• Kavivero: mortgage refinance, refinance break even, cash out refi
• Fluvenar: flood, fema, insurance